Cancer Treatment Reviews
Volume 26, Issue 3 , Pages 205-227 , June 2000

Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy

  • E.A. Lien

      Affiliations

    • Department of Biochemical Endocrinology, Section of Oncology, Haukeland University Hospital, Bergens, N-5021, Norway
    • ,
  • P.E. Lønning

      Affiliations

    • Department of Medicine, Section of Oncology, Haukeland University Hospital, Bergens, N-5021, Norway

References 

    REFERENCES
  1. Cole MP, Jones CTA, Todd IDH. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971;25:270–275
  2. Lancet. 1992;339:1–15
  3. Clarke M, Collins R, Davies C, Godwin J, Gray R, Peto R. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467
  4. J Natl Cancer Inst. 1996;88:1543–1549
  5. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998;352:93–97
  6. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98–101
  7. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast, Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–1388
  8. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189–2197
  9. Haynes B, Dowsett M. Clinical pharmacology of selective estrogen receptor modulators. Drug Aging. 1999;14:323–336
  10. Mitlak BH, Cohen FJ. Selective estrogen receptor modulators: a look ahead. Drugs. 1999;57:653–663
  11. Spencer CP, Morris EP, Rymer JM. Selective estrogen receptor modulators: women’s panacea for the next millenium?. Am J Obstet Gynecol. 1999;180:763–770
  12. Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, Montagna G, et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat. 1988;12:307–310
  13. Caleffi M, Fentiman IS, Clark GM, Wang DY, Needham J, Clark K, et al. Effect of tamoxifen on estrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol. 1988;119:335–339
  14. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990;82:1327–1332
  15. Dewar JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RAB. Long term effects of tamoxifen on blood lipid values in breast cancer. Br Med J. 1992;305:225–226
  16. Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P. Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer. 1994;73:659–663
  17. Anker G, Lønning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen. Int J Cancer. 1994;60:365–368
  18. Cattaneo M, Baglietto L, Zighetti ML, Bettega D, Robertson C, Costa A, et al. Tamoxifen reduces plasma homocysteine levels in healthy women. Br J Cancer. 1998;77:2264–2266
  19. Love RR, Anker G, Yang Y, Refsum H, Ueland PM, Lonning PE, et al. Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Lett. 1999;145:73–77
  20. Fornander T, Rutquist LE, Sjøberg HE, Blomquist L, Mattson A, Glas U. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol. 1990;8:1019–1024
  21. Love RR, Mazess RB, Barden HS, Epsein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852–856
  22. Wright CDP, Mansell RE, Gazet JC, Compston JE. Effect of long term tamoxifen treatment on bone turnover in women with breast cancer. Br Med J. 1993;306:429–430
  23. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78–84
  24. Bruning PF, Bonfrer JMG, Hart AAM. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer. 1988;58:497–499
  25. Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 1995;345:29–30
  26. Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR. Multicenter phase-II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol. 1993;11:345–350
  27. Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA, Dombernowsky P. Toremifene and tamoxifen in advanced breast cancer – a double-blind cross-over trial. Breast Cancer Res Treat. 1993;25:57–63
  28. Hudis C, Buzdar A, Munster P, Booser D, Theriault R, Frye D, et al. Phase I study of a third-generation selective estrogen receptor modulator (SERM3, LY353381.HCI) in refractory, metastatic breast cancer. Breast Cancer Res Treat. 1998;50:442
  29. Coombes RC, Haynes BP, Dowsett M, Quigley M, English J, Judson IR, et al. Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Res. 1995;55:1070–1074
  30. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17 beta-estradiol and raloxifene. Science. 1996;273:1222–1225
  31. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17 beta-estradiol and raloxifene (Vol 273, pg 1222, 1996). Science. 1997;275:1249–1249
  32. Grese TA, Pennington LD, Sluka JP, Adrian MD, Cole HW, Fuson TR, et al. Synthesis and pharmacology of conformationally restricted raloxifene analogues: Highly potent selective estrogen receptor modulators. J Med Chem. 1998;41:1272–1283
  33. BuelkeSam J, Bryant HU, Francis PC. The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing. Reprod Toxicol. 1998;12:217–221
  34. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641–1647 26–6
  35. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized study. J Bone Miner Res. 1998;13:1747–1754
  36. Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-de Roo GW, Jakobs C, Kenemans P. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril. 1998;70:1085–1089
  37. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445–1451
  38. Huster WJ, Boss SM, Glant MD, Eisenhut CC, Neild JA, Draper MW. Raloxifene does not cause endometrial proliferation in postmenopausal women. J Soc Gynecol Invest. 1996;3(Suppl. 2):147A
  39. Kiehr B, Christensen MS. Assay for levormeloxifene, a selective estrogen receptor modulator, in human and monkey plasma employing high-performance liquid chromatography and solid-phase extraction. J Chromatogr B Biomed Sci Appl. 1999;729:315–322
  40. Simard J, Sanchez R, Poirier D, Gauthier S, Singh SM, Merand Y, et al. Blocade of the stimulatory effects of estrogen, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma ishikawa cells. Cancer Res. 1997;57:3494–3497
  41. Simard J, Labrie C, Belanger A, Gauthier S, Singh SM, Merand Y, et al. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int J Cancer. 1997;73:104–112
  42. Tremblay GB, Tremblay A, Labrie F, Giguere V. Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res. 1998;58:877–881
  43. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998;50:151–196
  44. Lønning PE, Lien EA. Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol Hematol. 1995;21:158–193
  45. Kumar V, Green S, Stack G, Berry M, Jin J-R, Chambon P. Functional domains of the human estrogen receptor. Cell. 1987;51:941–951
  46. Webster NJG, Green S, Jin JR, Chambon P. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell. 1988;54:199–207
  47. Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai MJ, Edwards DP, et al. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem. 1998;273:12101–12108
  48. Dauvois S, Danielian PS, White R, Parker MG. Antioestrogen ICI 164384 reduced cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA. 1992;89:4037–4041
  49. Arbucle ND, Dauvois S, Parker MG. Effects of antioestrogens on the DNA binding activity of oestrogen receptors in vitro. Nucl Acid Res. 1992;20:3839–3844
  50. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867–3873
  51. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, EngstrØm O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753–758
  52. Hopp TA, Fuqua SAW. Estrogen receptor variants. J Mammary Gland Biol Neoplasi. 1998;3:73–83
  53. Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonnel DP, Nawaz Z, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991;51:105–109
  54. McNeil C. In search of the perfect SERM: beyond tamoxifen and raloxifene. J Natl Cancer Inst. 1998;90:956–957
  55. McInerney EM, Tsai MJ, Omalley BW, Katzenellenbogen BS. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci USA. 1996;93:10069–10073
  56. Treuter E, Albrektsen T, Johansson L, Leers J, Gustafsson JA. A regulatory role for RIP140 in nuclear receptor activation. Mol Endocrinol. 1998;12:864–881
  57. Berns MJJ, van Staveren IL, Klijn JGM, Foekens JA. Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res Treat. 1998;48:87–92
  58. Joyeux A, Cavailles V, Balaguer P, Nicolas JC. RIP 140 enhances nuclear receptor-dependent transcription in vivo in yeast. Mol Endocrinol. 1997;11:193–202
  59. Kalkhoven E, Valentine JE, Heery DM, Parker MG. Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J. 1998;17:232–243
  60. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 1996;93:5925–5930
  61. Mosselman S, Polman J, Dijkema R. ER β identification and characterization of a novel human estrogen receptor. FEBS Letters. 1996;392:49–53
  62. Dotzlaw H, Leygue E, Watson PH, Murphy LC. Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res. 1999;59:529–532
  63. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J, Pathol. 2000;156:29–35
  64. Chang WY, Prins GS. Estrogen receptor-beta: implications for the prostate gland. Prostate. 1999;40:115–124
  65. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson JA, Kushner PJ, et al. Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites. Science. 1997;277:1508–1510
  66. Lønning PE. Pharmacology of new aromatase inhibitors. Breast. 1996;5:202–208
  67. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst. 1998;90:1461–1467
  68. Decensi A, Gandini S, Guerrieri-Gonzaga A, Manetti L, Bonannai B, Barreca A, et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose dose reduction. J Clin Oncol. 1999;17:2633–2638
  69. Geisler J, Ekse D, Hösch S, Lønning PE. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol. 1995;55:193–195
  70. Geisler J, Lien EA, Ekse D, Lønning PE. Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol. 1997;63:53–58
  71. Helle SI, Anker G, Tally M, Hall K, Lønning PE. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulinlike growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Mol Biol. 1996;57:167–171
  72. Lønning PE, Hall K, Aakvaag A, Lien EA. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res. 1992;52:4719–4723
  73. Lien EA, Johannessen DC, Aakvaag A, Lønning PE. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. J Steroid Biochem Mol Biol. 1992;41:541–543
  74. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC. Alteration of endocrine parameters in premenopausal women with breast cancer during long term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst. 1991;83:1488–1491
  75. Jordan VC, Fritz NF, Tormey DC. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 1987;47:624–630
  76. Jordan VC, Fritz NF, Tormey DC. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antitrombin III. Cancer Res. 1987;47:4517–4519
  77. Lønning PE, Johannessen DC, Lien EA, Ekse D, Fotsis T, Adlercreutz H. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J Ster Biochem Mol Biol. 1995;52:491–496
  78. Gasparini G, Canobbio L, Galligioni E, Fassio T, Brema F, Crivellari D, et al. Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: therapeutic and endocrine effects in postmenopausal advanced breast cancer patients. Eur J Cancer Clin Oncol. 1987;23:1451–1459
  79. Luciani L, Oriana S, Spatti G, Secreto G, Recchione C, Grignoglio E, et al. Hormonal and receptor status in postmenopausal women with endometrial carcinoma before and after treatment with tamoxifen. Tumori. 1984;70:189–192
  80. Boccardo F, Guarneri D, Rubagotti A, Casertelli GL, Bentivoglio G, Conte N, et al. Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori. 1984;70:61–68
  81. Golander Y, Sternson LA. Paired-ion chromatographic analysis of tamoxifen and two major metabolites in plasma. J Chromatogr. 1980;181:41–49
  82. Mendenhall DW, Kobayashi H, Shih FML, Sternson LA, Higuchi T, Fabian C. Clinical analysis of tamoxifen, an anti-neoplastic agent, in plasma. Clin Chem. 1978;24:1518–1524
  83. Adam HK. Analysis of tamoxifen in biological samples. Symp Bologna (Oncol). 1985;83–89
  84. Daniel CP, Gaskell SJ, Bishop H, Nicholson RI. Determination of tamoxifen and an hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography – mass spectrometry. J Endocrinol. 1979;83:401–408
  85. Gaskell SJ, Daniel CP, Nicholson RI. Determination of tamoxifen in rat plasma by gas chromatography – mass spectrometry. J Endocrinol. 1978;78:293–294
  86. Daniel P, Gaskell SJ, Bishop H, Campbell C, Nicholson RI. Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur J Cancer Clin Oncol. 1981;17:1183–1189
  87. Murphy C, Fotsis T, Pantzar P, Adlercreutz H, Martin F. Analysis of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KCI-nuclear extracts of breast tumors from tamoxifen treated patients by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). J Steroid Biochem. 1987;28:609–618
  88. Lien EA, Solheim E, Kvinnsland S, Ueland PM. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 1988;48:2304–2308
  89. Girault J, Istin B, Fourtillan JB. Quantitative measurement of 4-hydroxy tamoxifen in human plasma and mammary tumours by combined gas chromatography/negative chemical ionization mass spectrometry. Biol Mass Spectrom. 1993;22:395–402
  90. Camaggi CM. High-performance liquid chromatographic analysis of tamoxifen and major metabolites in human plasma. J Chromatogr. 1983;275:436–442
  91. Brown RR, Bain R, Jordan VC. Determination of tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation. J Chromatogr. 1983;272:351–358
  92. Wilbur BJ, Benz CC, DeGregorio MW. Quantitation of tamoxifen, 4-hydroxytamoxifen, and N-desmethyltamoxifen in human plasma by high performance liquid chromatography. Anal Letters. 1985;18:1915–1924
  93. Lien EA, Ueland PM, Solheim E, Kvinnsland S. Determination of tamoxifen and four metabolites in serum by low-dispersion liquid chromatography. Clin Chem. 1987;33:1608–1614
  94. Milano G, Etienne MC, Frenay M, Khater R, Formento JL, Renee N, et al. Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. Br J Cancer. 1987;55:509–512
  95. Stevenson D, Briggs RJ, Chapman DJ, de Vos D. Determination of tamoxifen and five metabolites in plasma. J Pharmaceut Biomed Anal. 1988;6:1065–1068
  96. Langan-Fahey SM, Douglass C, Tormey DC, Jordan VC. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer. 1990;26:883–888
  97. Nieder M, Jaeger H. Quantification of tamoxifen and N-desmethyltamoxifen in human plasma by high-performance liquid chromatography, photochemical reaction and fluorescence detection, and its application to biopharmaceutical investigations. J Chromatogr. 1987;413:207–217
  98. Lim CK, Yuan ZX, Lamb JH, White INH, Dematteis F, Smith LL. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis. 1994;15:589–593
  99. Lim CK, Chow LCL, Yuan ZX, Smith LL. High performance liquid chromatography of tamoxifen and metabolites in plasma and tissues. biomed Chromatogr. 1993;7:311–314
  100. Lim CK, Yuan ZX, Ying KC, Smith LL. High performance liquid chromatography of toremifene and metabolites. J Liq Chromatogr. 1994;17:1773–1783
  101. Soe L, Wurz GT, Mäenpää JU, Hubbard GB, Cadman TB, Wiebe VJ, et al. Tissue distribution of transdermal toremifene. Cancer Chemother Pharmacol. 1997;39:513–520
  102. Lien EA, Anker G, Lønning PE, Ueland PN. Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Ther Drug Monit. 1994;17:259–265
  103. Tess DA, Cole RO, Toler SM. Sensitive method for the quantitation of droloxifene in plasma and serum by high-performance liquid chromatography employing fluorimetric detection. J Chromatogr B Biomed Appl. 1995;674:253–260
  104. Manns JE, Hanks S, Brown JE. Optimised separation of E-, Z-isomers of tamoxifen, and its principal metabolites using reversed-phase high performance liquid chromatography. J Pharm Biomed Anal. 1998;16:847–852
  105. Lindstrom TD, Whitaker NG, Whitaker GW. Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys. Xenobiotica. 1984;14:841–847
  106. Matlin SA, Thomas C, Vince PM. Anti-hormonal agents. VI. Direct plasma analyses of tamoxifen by HPLC using an on-line ISRP extraction cartridge. J Liquid Chromatogr. 1990;13:2253–2260
  107. Merle O, Faure N, Guitton J, Burke MD, Ollagnier M. Solid phase extraction and high performance liquid chromatography of tamoxifen and its demethylated metabolites in plasma. Analyt Lett. 1998;31:2679–2690
  108. Merle O, Guitton J, Burke MD, Ollagnier M. Rapid and simple method to determine tamoxifen and its major metabolites in human liver microsomesby high performance liquid chromatography with fluorescence detection. Anal Lett. 1998;31:2067–2076
  109. Jank P, Kern D, Huber HJ, Stanislaus F. Direct determination of droloxifene in serum using HPLC with precolumn switching, post-column photochemical derivatization and fluorescence detection. Third European congress of biopharmaceutics and pharmacokinetics. Proceedings. In:  Aiache JM,  Hirtz J editor. Pharmaceutics. France: Clermont-Ferrand; 1987;p. 511–520
  110. MacCallum J, Cummings J, Dixon JM, Miller WR. Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma. J Chromatogr. 1996;678:317–323
  111. Holleran WM, Gharbo SA, DeGregorio MW. Quantitation of toremifene and its major metabolites in human plasma by high performance liquid chromatography following fluoriscent activation. Anal Lett. 1983;20:871–879
  112. Wurz GT, Soc L, Emshoff VD, Cadman TB, DeGregorio MW. Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin. Cancer Chemother Pharmacol. 1998;42:363–366
  113. Webster LK, Crinis NA, Stokes KH, Bishop JF. High-performance liquid chromatographic method for the determination of toremifene and its major human metabolites. J Chromatogr. 1991;565:482–487
  114. Adam HK, Douglas EJ, Kemp JV. The metabolism of tamoxifen in humans. Biochem Pharmacol. 1979;27:145–147
  115. Adam HK, Patterson JS, Kemp JV. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep. 1980;64:761–764
  116. Adam HK, Gay MA, Moore RH. Measurement of tamoxifen in serum by thin-layer densitometry. J Endocrinol. 1980;84:35–42
  117. Kemp JV, Adam HK, Wakeling AE, Slater R. Identification and biological activity of tamoxifen metabolites in human serum. Biochem Pharmacol. 1983;32:2045–2052
  118. Lim HK, Stellingweif S, Sisenwine S, Chan KW. Rapid drug metabolite profiling using fast liquid chromatography, automated multiple-stage mass spectrometry and receptor-binding. J Chromatogr A. 1999;831:227–241
  119. Sanders JM, Burka LT, Shelby MD, Newbold RR, Cunningham ML. Determination of tamoxifen and metabolites in serum by capillary electrophoresis using a nonaqueous buffer system. J Chromatogr. 1997;695:181–185
  120. Martinsen A, Gynther J. Liquid chromatography-thermospray mass spectrometry of toremifene and its derivatives. J Chromatogr A. 1996;724:358–363
  121. Lu W, Poon GK, Carmichael PL, Cole RB. Analysis of tamoxifen and its metabolites by on-line capillary electrophoresis-electrospray ionization mass spectrometry employing nonaquous media containing surfactants. Anal Chem. 1996;68:668–674
  122. Boxenbaum H, DiLea C. First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol. 1995;35:957–966
  123. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos. 1991;19:36–43
  124. Lien EA, Anker G, Lønning PE, Solheim E, Ueland PM. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 1990;50:5851–5857
  125. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989;49:2175–2183
  126. Burchell B, Coughtrie MWH. UDP-glucuronosyltransferases. Pharmacol Therap. 1989;43:261–289
  127. Fromson JM, Pearson S, Bramah S. The metabolism of tamoxifen. (I.C.I. 46,474) Part II: in female patients. Xenobiotica. 1973;3:711–714
  128. Fromson JM, Pearson S, Bramah S. The metabolism of tamoxifen. (I.C.I. 46,474) Part I: in laboratory animals. Xenobiotica. 1973;3:693–709
  129. Tanaka Y, Sekiguchi M, Sawamoto T, Hata T, Esumi Y, Sugai S, et al. Pharmacokinetics of droloxifene in mice, rats, monkeys, premenopausal and postmenopausal patients. Eur J Drug Metab Pharm. 1994;19:47–58
  130. Knadler MP, Lantz RJ, Gillespie TA, Allerheiligen SRB, Henry DP. The disposition and metabolism of 14C-labeled raloxifene in humans. Pharm Res. 1995;12(suppl):S–372
  131. Ni L, Allerheiligen SRB, Basson R, Al E. Pharmacokinetics of raloxifene in men and postmenopausal women volunteers. Pharmacol Res. 1996;13(Suppl):430
  132. Anttila M, Valavaara R, Kivinen S, Mäenpää J. Pharmacokinetics of toremifene. J Steroid Biochem. 1990;36:249–252
  133. McCague R, Parr IB, Leclerq G, Leung O-T, Jarman M. Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen. Biochem Pharmacol. 1990;39:1459–1465
  134. McCague R, Parr IB, Haynes BP. Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites. Biochem Pharmacol. 1990;40:2277–2283
  135. Fabian C, Sternson L, Barnett M. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep. 1980;64:765–773
  136. Grill HJ, Pollow K. Pharmacokinetics of droloxifene and its metabolites in breast cancer patients. Am J Clin Oncol. 1991;14 (Suppl 2):21–29
  137. Stamm H, Roth R, Huber H-J, Jank P, Löser R, Seibel K, et al. Preliminary data on phase-I trial of the new antiestrogen droloxifene: tolerance, pharmacokinetics and metabolism. Contr Oncol. 1986;23:73–78
  138. Sipilä H, Kangas L, Vuorilehto L, Kalapudas A, Eloranta M, Södervall M, et al. Metabolism of toremifene in the rat. J Steroid Biochem. 1990;36:211–215
  139. Kangas L. Review of the pharmacological properties of toremifene. J Steroid Biochem. 1990;36:191–195
  140. Data on file, Lilly Research Laboratories, Eli Lilly and Company Limited.
  141. Bratherton DG, Brown CH, Buchanan R, Hall V, Kinsley Pillers EM, Wheeler TK, et al. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal woman with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer. 1984;50:199–205
  142. Peyrade F, Frenay M, Etienne MC, Ruch F, Guillemare C, Francois E, et al. Age-related difference in tamoxifen disposition. Clin Pharmacol Ther. 1996;59:401–410
  143. Tominaga T, Abe O, Izuo M, Nomura Y. A phase I study of toremifene. Breast Cancer Res Treat. 1990;16S:27–29
  144. Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregorio MW. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol. 1990;25:247–251
  145. Wiseman LR, Goa KL. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs. 1997;54:141–160
  146. Bishop J, Murray R, Webster L, Pitt P, Stokes K, Fennesy A, et al. Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol. 1992;30:174–178
  147. Robinson SP, Parker CJ, Jordan VC. Preclinical studies with toremifene as an antitumor agent. Breast Cancer Res Treat. 1990;16:S9–S17
  148. Stuart NSA, Philip P, Harris AL, Tonkin K, Houlbrook S, Kirk J, et al. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer. 1992;66:833–839
  149. Nickerson DF, Toler SM. Intrapertioneal and intraportal administration of droloxifen to the sprague-dawley rat: assessing the first-pass effect. Xenobiotica. 1997;27:627–632
  150. Patterson JS, Settatree RS, Adam HK, Kemp JV. Serum concentrations of tamoxifen and major metabolite during long term nolvadex therapy, correlated with clinical response. In:  Mouridsen HT,  Palshof T editor. Breast Cancer-Experimental and Clinical Aspects.. Oxford: Pergamon Press; 1980;p. 89–92
  151. Pang KS, Gillette JR. Metabolite pharmacokinetics: Methods for simultaneous estimates of elimination rate constants of a drug and its metabolite. Drug Metab Dispos. 1980;8:39–43
  152. Pang KS. A review of metabolite kinetics. J Pharmacokin Biopharm. 1985;13:633–662
  153. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 1991;51:4837–4844
  154. Browne TR, Greenblatt DJ, Schumacher GE, Szabo GK, Evans JE, Evans BA. New pharmacokinetic methods III. Two simple tests for “deep pool effect”. J Clin Pharmacol. 1990;30:680–685
  155. Kohler PC, Hamm JT, Wiebe WJ, DeGregorio MV, Shemano I, Toremey DC. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer. Breast Cancer Res Treat. 1990;16:S19–S26
  156. Balfour JA, Goa KL. Raloxifene. Drugs Aging. 1998;12:335–341
  157. Allerheiligen S, Geiser J, Knadler M, Al E. Raloxifene pharmacokinetics and the associated endocrine effects in premenopausal women treated during the follicular, ovulatory, and luteal phases of the menstrual cycle [abstract]. Pharmacol Res. 1996;13(Suppl).:430
  158. Haynes, B. P. Grimshaw, R. M. Griggs, L. J. Hardcastle, I. Nutley, B. P. Jarman, M. Johnston, S. R. D. Twelves, C. J. Soukop, M. Rea, D. W. Howel, A. Jones, A. Coombes, R. C. Pharmacokinetics of idoxifene and tamoxifen in a randomised phase II trial in breast cancer patients who have relapsed on tamoxifen. 10th NCI-EORTC symposium on new drugs in cancer therapy, June 16–19, Amsterdam 1998
  159. Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM. High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature. 1980;288:273–275
  160. Wiseman H, Laughton MJ, Arnstein HRV, Cannon M, Halliwell B. The antioxydant action of tamoxifen and its metabolites. Inhibition of lipid peroxidation. FEBS Lett. 1990;263:192–194
  161. Raymond GG, Born JL. An updated pKa listing of medicinal compounds. Drug Intell Clin Pharmacy. 1986;20:683–686
  162. Shah IG, Parsons DL. Human albumin binding of tamoxifen in the presence of a perfluorochemical erythrocyte substitute. J Pharm Pharmacol. 1991;43:790–793
  163. Osborne CK. Toremifene – panel discussion and summary. Breast Cancer Res Treat. 1990;16:S47–S54
  164. Kremer JMH, Wilting J, Janssen LHM. Drug binding to human alpha-1-acid glycoprotein in health and desease. Pharmacol Rev. 1988;40:1–47
  165. Chatterjee M, Harris AL. Reversal of acquired resistance to adriamycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen: role of drug interaction with alpha 1 acid glycoprotein. Br J Cancer. 1990;62:712–717
  166. Lønning PE, Lien EA, Lundgren S, Kvinnsland S. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet. 1992;22:327–358
  167. Lien EA, Wester K, Lønning PE, Solheim E, Ueland PM. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer. 1991;63:641–645
  168. Wilking N, Appelgren E, Carlström K, Nordgren T, Theve T. The distribution and metabolism of 14 C-labelled tamoxifen in spayed female mice. Rev Endocrinol Rel Cancer. 1981;9:233–239
  169. Wilking N, Appelgren L-E, Carlström K, Pousette Å, Theve NO. The distribution and metabolism of14C-labelled tamoxifen in spayed female mice. Acta Pharmacol Toxicol. 1982;50:161–168
  170. Lin JH. Species similarities and differences in pharmacokinetics. Drug Metab Dispos. 1995;23:1008–1021
  171. d’Argy R, Paul R, Frankenberg L, Stålnacke C-G, Lundquist H, Kangas L, et al. Comparative double-tracer whole-body autoradiography: uptake of11C-,18F- and3H-labeled compounds in rat tumors. Nucl Med Biol. 1988;15:577–585
  172. Young H, Carnochan P, Trivedi M, Potter GA, Eccles SA, Haynes BP, et al. Pharmacokinetics and biodistribution of radiolabelled idoxifene: prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapy. Nucl Med Biol. 1995;22:405–411
  173. Katzenellenbogen JA, Carlson KE, Katzenellenbogen BS. Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers. J Steroid Biochem. 1985;22:589–596
  174. Robertson DW, Katzenellenbogen JA, Long DJ, Rorke EA, Katzenellenbogen BS. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem. 1982;16:1–13
  175. Jordan V, Bain RR, Brown RR, Gosden B, Santos MA. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res. 1983;43:1446–1450
  176. Kangas L. Biochemical and pharmacological effects of toremifene metabolites. Cancer Chemother Pharmacol. 1990;27:8–12
  177. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol. 1995;40:523–530
  178. Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol. 1997;53:171–178
  179. Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 1997;57:3402–3406
  180. Wisemann H, Lewis DFV. The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: potential importance to its proposed anti-carcinogenic/carcinogenic actions. Carcinogenesis. 1996;17:1357–1360
  181. Relling MV. Polymorphic drug metabolism. Clin Pharm. 1989;8:852–863
  182. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos. 1996;24:899–905
  183. Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther. 1998;64:648–654
  184. Löser R, Seibel K, Liehn HD, Staab H-J. Pharmacology and toxicology of the antiestrogen droloxifene. Contributions to Oncology. 1986;23:64–72
  185. Löser R, Seibel K, Huber HJ. Pharmacological activities of droloxifene isomers. Anticancer Res. 1988;8:1271–1274
  186. McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M, et al. Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. J Med Chem. 1989;32:2527–2533
  187. Haynes BP, Griggs LJ, Grimshaw RM, Quigley M, Nutley BP, Poon GK, et al. Pharmacokinetics of idoxifene and identification of metabolites in patients during a loading dose study. Proc Amer Assoc Cancer Res. 1996;37:117
  188. Dodge JA, Lugar CW, Cho S, Short LL, Sato M, Yang NN, et al. Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Mol Biol. 1997;61:97–106
  189. O’Donnell JP, Khosla NB, Dalvie DK. Metabolism of droloxifene in the CD-1 mouse, Fischer-344 rat and cynomolgus monkey. Xenobiotica. 1998;28:153–166
  190. Gorbach SL. Function of the normal human microflora. Scand J Infect Dis Suppl. 1986;49:17–30
  191. Scheline RR. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev. 1973;25:451–523
  192. Lien EA, Anker G, Ueland PM. Pharmacokinetics of tamoxifen in pre-and post-menopausal women with breast cancer. J Ster Mol Biol. 1995;55:229–231
  193. Sotaniemi EA, Anttila MI. Influence of age on toremifene pharmacokinetics. Cancer Chemother Pharmacol. 1997;40:185–188
  194. Sutherland CM, Sternson LA, Muchmore JH, Ball JE, Cerise EJ. Effect of impaired renal function on tamoxifen. J Surg Oncol. 1984;27:222–223
  195. DeGregorio MW, Wiebe VJ, Venook AP, Holleran WM. Elevated plasma tamoxifen levels in a patient with liver obstruction. Cancer Chemother Pharmacol. 1989;23:194–195
  196. Al-Turk WA, Stohs SJ, Roche EB. Effect of tamoxifen treatment on liver, lung and intestinal mixed-function oxydases in male and female rats. Drug Metab Dispos. 1981;9:327–330
  197. Borgna J-L, Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem. 1981;256:859–868
  198. Camaggi CM, Strocchi E, Pannuti F. Tamoxifen pharmacokinetics in advanced breast cancer patients. In:  Pannuti F editors. Anti-oestrogens in oncology. Past, Present and Prospects.. Amsterdam: Excerpta Medica; 1985;p. 90–97
  199. Meltzer NM, Stang P, Sternson LA. Influence of tamoxifen and its N-desmethyl and 4-hydroxy metabolites on rat liver microsomal enzymes. Biochem Pharmacol. 1984;33:115–123
  200. Ruenitz PC, Bagley JR, Pape CW. Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metab Dispos. 1984;12:478–483
  201. Lodwick R, McConkey B, Brown AM, Beeley L. Life threatening interactions between tamoxifen and warfarin. Br Med J. 1987;295:1141
  202. Ritchie LD, Grant SMT. Tamoxifen-warfarin interaction: the Aberdeen hospitals drug file. Br Med J. 1989;298:1253
  203. Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. Br Med J. 1989;298:93
  204. Middeke M, Remien C, Lohmøller G, Holzgreve H, Zøllner N. Interaction between tamoxifen and digitoxin?. Klin Wochenschr. 1986;64:1211
  205. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthau F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol. 1991;41:1911–1919
  206. Berthou F, Dreano Y, Belloc C, Kangas L, Gautier J-C, Beaune P. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharm. 1994;47:1883–1895
  207. White JNH, de Matteis F, Gibbs AH, Lim CK, Wolf CR, Henderson C, et al. Species differences in the covalent binding of (14C)tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem Pharm. 1995;49:1035–1042
  208. Dehal SS, Brodie AM, Kupfer D. The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy. Drug Metab Dispos. 1999;27:389–394
  209. Zaccheo T, Giudici D, Disalle E. Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-Induced mammary tumors in rats. J Steroid Biochem Mol Biol. 1993;44:677–680
  210. Lu Q, Liu Y, Long BJ, Grigoriev D, Gimbel M, Brodie A. The effect of combining aromatase inhibitors antioestrogens on tumour growth in a nude mice model for breast cancer. Breast Cancer Res Treat. 1999;57:183–192
  211. Lundgren S, Lønning PE, Aakvaag A, Kvinnsland S. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in post-menopausal patients with advanced breast cancer. Cancer Chemother Pharmacol. 1990;27:101–105
  212. Deijk WAv, Blijham GH, Mellink WAM, Meulenberg PMM. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol. Cancer Treat Rep. 1985;69:85–90
  213. Murray M, Cantrill E, Farrell GC. Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide. J Pharmacol Exp Ther. 1993;265:477–481
  214. Lønning PE. Aminoglutethimide enzyme induction: pharmacologial and endocrinological implications. Cancer Chemother Pharmacol. 1990;26:241–244
  215. Murray M, Cantrill E, Farrell GC. Induction of Cytochrome-P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide. J Pharmacol Exp Ther. 1993;265:477–481
  216. Grimm SW, Dyroff MC. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos. 1997;25:598–602
  217. St. Peter J, Pharm D, Thyrum P, Yeh C, Dyroff M, Selen A. Lack of effect of anastrozole, an aromatase inhibitor, on antipyrine pharmacokinetics in postmenopausal women. Clin Pharmacol Therap. 1997;61:172
  218. Dowsett M, Tobias JS, Howell A, Blackman GM, Welch H, King N, et al. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. Br J Cancer. 1999;79:311–315
  219. Ingle JN, Suman VJ, Johnson PA, Krook JE, Mailliard JA, Wheeler RH, et al. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res. 1999;5:1642–1649
  220. Dowsett M, Pfister C, Johnston SRD, Miles DW, Houston SJ, Verbeek JA, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromataseinhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res. 1999;5:2338–2343
  221. Camaggi CM, Strocchi E, Canova N, Costanti B, Pannuti F. Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with ‘low’ TMX and ‘high’ MAP doses. Cancer Chemother Pharmacol. 1985;14:229–331
  222. Gradishar WJ, Glusman JE, Vogel CL, Mansi JL, Stuart NSA, Carmichael J, et al. Raloxifene HCI, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer. Breast Cancer Res Treat. 1997;46:53
  223. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks F. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196–1204
  224. Trial TWGftP. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1995;273:199–208
  225. Jensen J, Christiansen C. Dose-response effects on serum lipids and lipoproteins following combined oestrogen-progestogen therapy in post-menopausal women. Maturitas. 1987;9:259–266
  226. Perrone G, Falaschi P, Capri O, Pastore R, Galoppi P, D’Urso R, et al. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. Int J Fertil. 1994;39:202–207
  227. Elkik F, Gompel A, Mercier-Bodard C, Kuttenn F, Guyenne PN, Corvol P, et al. Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in postmenopausal women. Am J Obstet Gynecol. 1982;143:888–892
  228. Holst J, Cajander S, Carlström K, Damber M-G, Schoultz Bv. A comparison of liver protein induction in postmenopausal women during oral and percutaneous oestrogen replacement therapy. Br J Obstet Gynecol. 1983;90:355–360
  229. Helle SI, Omsjø IH, Hughes SCC, Botta L, Hüls G, Holly JMP, et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol. 1996;45:727–732
  230. Caruso MG, Berloco P, Notarnicola M, Leo AD. Lipoprotein(a) serum levels in post-menopausal women treated with oral estrogens administered at different times. Horm Metab Res. 1994;26:379–382
  231. Farish E, Rolton HA, Barnes JF, Fletcher CD, Walsh DJ, Spowart KJM, et al. Lipoprotein(a) and postmenopausal oestrogen. Acta Endocrinol. 1993;129:225–228
  232. Mendoza S, Velazquez E, Osona A, Hamer T, Glueck CJ. Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein (a). J Lab Clin Med. 1994;123:837–841
  233. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Nat Cancer Inst. 1994;86:1534–1539
  234. Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Treleaven JG, et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol. 1996;7:671–675
  235. Gylling B, Pyrhönen S, Mäntylä E, Mäenpää H, Kangas L, Miettinen TA. Tamoxifen, toremifen lower serum cholesterol by inhibition ao delta8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol. 1995;13:2900–2905
  236. Saarto T, Blomqvist C, Ehnholm C, Taskinen M-R, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol. 1996;14:429–433
  237. Brun LD, Gagne C, Rousseau C, Moorjani S, Lupien PJ. Severe lipemia induced by tamoxifen. Cancer. 1986;57:2123–2126
  238. Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab. 1998;83:1633–1635
  239. Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S. Tamoxifen-induced fatty liver in patients with breast cancer [letter]. Lancet. 1998;351:725
  240. Mooren MJvd, Wouters MGAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest. 1994;24:733–736
  241. Mijatovic V, Kenemans P, Jakobs C, VanBaal MV, PetersMuller ER, VanderMooren MJ. A randomized controlled study of the effects of 17beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol. 1998;91:432–436
  242. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31–62
  243. Lipton A, Morris ID. Calcium antagonism by the antiestrogen tamoxifen. Cancer Chemother Pharmacol. 1986;18:17–20
  244. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ. 1995;311:977–980
  245. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Nat Cancer Inst. 1997;89:776–782
  246. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst. 1993;85:1398–1406
  247. Sherman BM, Chapler FK, Crickard K, Wycoff D. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest. 1979;64:398–404
  248. Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S, Elomaa I. Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer. 1997;75:602–605
  249. Draper MW, Flowers DF, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY 139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11:835–842
  250. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–1037
  251. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994;343:1318–1321
  252. Cohen I, Altaras MM, Shapira J, Tepper R, Rosen DJD, Cordoba M, et al. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. Int J Gyn Pathol. 1996;15:152–157
  253. Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol. 1995;59:261–266
  254. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–1618
  255. Shushan A, Peretz T, Uziely B, Lewin A, Mor-Yosef S. Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol. 1996;174:141–144
  256. Cohen I, Rosen DJD, Altaras M, Beyth Y, Shapira J, Yigael D. Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth. Br J Cancer. 1994;69:620–621
  257. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, et al. Endometrial cancer in Tamoxifen-Treated breast cancer patients – findings from the national surgical adjuvant breast and bowel project (NSABP) b-14. J Nat Cancer Inst. 1994;86:527–537
  258. Rutquist LE, Johansson H, Signomklao H, Johanssson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm breast cancer study group. J Natl Cancer Inst. 1995;87:645–651
  259. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529–1542
  260. Jordan VC, Assikis VJ. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res. 1995;1:467–472
  261. Fornander T, Cedermark B, Mattsson A, Skoog L, Theve T, Askergren J, et al. Adjuvant tamoxifen in early breast cancer: occurence of new primary cancers. Lancet. 1989;1:117–120
  262. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis. 1993;14:315–317
  263. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, et al. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl-CD(BR) rats. Cancer Res. 1993;53:4534–4541
  264. Hemminki K, Rajaniemi H, Lindahl B, Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 1996;56:4374–4377
  265. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993;11:485–490
  266. Barakat R. Tamoxifen and endometrial cancer: most cancers are early stage and highly curable. Eur J Cancer. 1998;34:S49–S50
  267. Davies GC, Huster WJ, Lu Y, Plouffe L, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999;93:558–565
  268. Cohen F, Watts S, Beymer K, Al E. Vaginal complaints in healthy postmenopausal women: data from a 3-year trial comparing raloxifene with conjugated estrogens or placebo. Program of the North American Menopause Society, Toronto, CA,. 1998;
  269. Baker VL, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J, et al. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab. 1998;83:6–13
  270. Novo, Nordisk. Bagsvaerd, D. Novo Nordisk levormeloxifene phase 2 clinical trial: Novo Nordisk presents phase 2 data on levormeloxifen to clinical investigators [press release]. PRNewswire 1998 June 19.
  271. Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocrine Rev. 1990;11:221–265
  272. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer. 1998;83:1142–1152
  273. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16:453–461
  274. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Cervek J, et al. Survival advantage of exemestane (AromasinR) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study. Proc Am Soc Clin Oncol. 1999;18:412
  275. Robertson JFR, Howell A, De Friend DJ, Blamey RW, Walton P. Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer. Breast. 1997;6:186–189
  276. Pyrhonen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the ‘nordic’ phase III study. Br J Cancer. 1997;76:270–277
  277. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995;13:2556–2566
  278. Bruning PF. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer – preliminary results of a double-blind dose-finding phase-II trial. Eur J Cancer. 1992;28A:1404–1407
  279. Haarstad H, Lønning PE, Gundersen S, Wist E, Raabe N, Kvinnsland S. Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment. Acta Oncol. 1998;37:365–368
  280. Haarstad H, Gundersen S, Wist E, Raabe N, Mella O, Kvinnsland S. Droloxifene – a new anti-estrogen. Acta Oncol. 1992;31:425–428
  281. Buzdar AU, Marcus C, Holmes F, Hag V, Hortobagyi G. Phase II evaluation of Ly 156756 in metastatic breast cancer. Oncology. 1988;45:344–345
  282. Baum M, Brinkley DM, Dossett JA. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet. 1985;1:836–840
  283. Powles TJ, Tillyer CR, Jones AL, Ashley SE, Treleaven J, Davey JB, et al. Prevention of breast cancer with tamoxifen-an update on the Royal Marsden Hospital pilot programme. Eur J Cancer. 1990;26:680–684
  284. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000
  285. Powles TJ. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Nat Cancer Inst. 1999;91:730
  286. Pritchard KI. Is tamoxifen effective in prevention of breast cancer?. Lancet. 1998;352:80–81
  287. Recht A, Silen W, Schnitt SJ, Connolly JL, Gelman RS, Rose MA, et al. Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1988;15:255–261
  288. Cuzick J. Primary prevention international tamoxifen study to continue. Lancet. 1998;352:1138
  289. Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics. 1992;1:20–32
  290. Smith TJ, Hillner BE. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. J Clin Oncol. 2000;18:284–286
  291. Cosman F, Lindsay R. Selective estrogen receptor modulators: Clinical spectrum. Endocrine Rev. 1999;20:418–434
  292. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene. J Clin Oncol. 1999;17:1939
  293. Fisher B, Costantino J, Redmond C, Poisson R. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. New Engl J Med. 1989;320:479–484
  294. Heel RC, Brogden RN, Speight TM, Avery GS. Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs. 1978;16:1–24
  295. Mouridsen HT, Palshof T, Patterson J, Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat Rev. 1978;5:131–141
  296. Sawka CA, Pritchard KI, Paterson AH, Sutherland DJ, Thomson DB, Shelley WE, et al. Role, mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res. 1986;46:3152–3156
  297. Love RR, Cameron L, Conell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991;151:1842–1847
  298. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9:286–294
  299. Br J Cancer. 1988;57:608–611
  300. Weitz IC, Israel VK, Liebman HA. Tamoxifen associated venous thrombosis and activated protein C resistance due to factor Leiden. Cancer. 1997;79:2024–2027
  301. Nickelsen T, Lufkin EG, Riggs BL, Cox DA, Crook TH. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology. 1999;24:115–128
  302. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep. 1978;62:315–320
  303. Longstaff S, Sigurdsson H, O’Keeffe M, Ogston S, Preece P. A controlled study on the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol. 1989;25:1805–1808
  304. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol. 1996;14:1018–1026
  305. Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998;125:493–501
  306. Chern S, Danis RP. Retinopathy associated with low-dose tamoxifen. Am J Ophthalmol. 1993;116:372–373
  307. Griffiths MFP. Tamoxifen retinopathy at low dosage. Am J Ophthalmol. 1987;8:185–186
  308. Cunha GR, Taguchi O, Namikawa R, Nishizuka Y, Robboy SJ. Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract. Hum Pathol. 1987;18:1132–1143
  309. IARC Monogr Eval Carcinog Risks Hum. 1996;66:253–365
  310. Iguchi T, Hirokawa M, Takasugi N. Occurence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen. Toxicol. 1986;42:1–11
  311. Iguchi T, Irisawa S, Uesugi Y, Kusunoki S, Takasugi N. Abnormal development of the os penis in male mice treated neonatally with tamoxifen. Acta Anat. 1990;139:201–208
  312. Tewari K, Bonebrake RG, Asrat T, Shanberg AM. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet. 1997;350:183
  313. Reilly JJ, Workman P. Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research. Cancer Chemother Pharmacol. 1994;34:3–13

PII: S0305-7372(99)90162-7

doi: 10.1053/ctrv.1999.0162

Cancer Treatment Reviews
Volume 26, Issue 3 , Pages 205-227 , June 2000

Article Tools